[{"orgOrder":0,"company":"Leo Pharma","sponsor":"Oneness Biotech","pharmaFlowCategory":"D","amount":"$570.0 million","upfrontCash":"$40.0 million","newsHeadline":"LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Kubota Vision Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kubota Vision Announces Signing of Open Innovation Agreement with LEO Pharma ","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"DENMARK","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Presents Phase 3 Data in Atopic Dermatitis and Plaque Psoriasis at the American Academy of Dermatology Virtual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces European Medicines Agency Acceptance of Marketing Authorization Application for tralokinumab to Treat Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces U.S. FDA Acceptance of Biologics License Application for Tralokinumab for Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"UNION therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UNION Therapeutics Announces Acquisition of PDE4i Compound Class from LEO Pharma with Oral Lead Candidate (orismilast) in Phase 2","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Gets U.S. FDA Fast Track Designation for delgocitinib Cream for the Treatment of Adults With Moderate-to-severe Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","amount":"$357.0 million","upfrontCash":"Undisclosed","newsHeadline":"Leo Pharma Sells Portfolio of Four Products to Cheplapharm","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces British Journal of Dermatology Publication of Three Pivotal Ph 3 Trials of Tralokinumab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces U.S. FDA Approval for Enstilar\u00ae (Calcipotriene and Betamethasone Dipropionate) Foam U.S. Prescribing Information Update to Include Data in Long-Term Use in Plaque Psoriasis Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma to Highlight New Data in Medical Dermatology at EADV Virtual 2020","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Reports Results of Phase 2b Dose-Finding Study with Delgocitinib cream in Patients with Mild-to-Severe Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Presents Data for Tralokinumab on Pooled Safety, S. Aureus Colonization Reduction and Impact on Vaccine Response Rates","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Biologics Announces Publication of Results from LUMEVOQ\u00ae RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Receives Positive CHMP Opinion of Adtralza\u00ae (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Starts first Phase 3 Clinical Trial with Delgocitinib Cream in Adult Patients with Moderate-To-Severe Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Presents New Adtralza\u00ae (tralokinumab) Data Following Long-Term Continuous Treatment At EADV 30th Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adtralza\u00ae (Tralokinumab) Achieves Primary and Secondary Endpoints in Phase 3 Trial of Adolescents With Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma announces FDA approval of Adbry\u2122 (tralokinumab-ldrm) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Initiates a Phase 2b Dose-Ranging Clinical Trial With an Oral H4R Antagonist in Adult Patients With Moderate-to-Severe Atopic Dermatitis (AD)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Presents New Interim Long-Term Safety and Efficacy Data for Adbry\u2122 (tralokinumab-ldrm) in Moderate-to-Severe Atopic Dermatitis at the 2022 AAD Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Sequence Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sequence Bio Announces Discovery Collaboration Agreement with LEO Pharma","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"DENMARK","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leo Pharma Announces European Commission Approval of Adtralza\u00ae (Tralokinumab) as the First and Only Treatment Specifically Targeting Il-13 for Adults With Moderate-to-severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces Publication of Adbry\u2122 (tralokinumab-ldrm) Efficacy Data in Moderate-to-Severe Atopic Dermatitis in American Journal of Clinical Dermatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leo Pharma to Present New Data in Moderate-to-severe Atopic Dermatitis and Chronic Hand Eczema at the 31st EADV Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Presents New Adtralza\u00ae Safety Data in Moderate-to-Severe Atopic Dermatitis at the 31st EADV Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Receives Positive CHMP Opinion of Adtralza\u00ae (tralokinumab) for the Treatment of Adolescents With Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"DKSH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LEO Pharma and DKSH Partner to Deliver Products and Solutions to People in Asia with Skin Conditions and Thrombosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces British Journal of Dermatology Publication of Adbry\u2122 (tralokinumab-ldrm) Pooled Safety Data in Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces Positive Phase 3 Topline Results From DELTA 1 Trial With Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (CHE)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan Ministry of Health, Labor and Welfare Approves Manufacturing and Marketing of Adtralza\u00ae (tralokinumab) in Japan for Adults with Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces Positive Phase 3 Topline Results From DELTA 2 Trial With Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (CHE), Confirming the Positive Results of the Recent DELTA 1 Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Presents Late-Breaking Positive Phase 2a Efficacy and Safety Results of LEO 138559 in Moderate-to-Severe Atopic Dermatitis at the 2023 AAD Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Receives Positive CHMP Opinion for New Adtralza (tralokinumab) Injection Device","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Timber Pharmaceuticals","pharmaFlowCategory":"D","amount":"$36.0 million","upfrontCash":"$14.0 million","newsHeadline":"LEO Pharma Signs Agreement to Acquire Timber Pharmaceutical","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Argenx","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Temtokibart Achieves First Subject First Treatment (FSFT) Milestone in Phase 2b trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces Positive Outcome of DELTA 3 Open-Label Extension Trial of Delgocitinib Cream in the Treatment of Adults With Moderate to Severe Chronic Hand Eczema (CHE)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces Positive Phase 3 Head-to-head Data Results from DELTA FORCE Trial Comparing Delgocitinib Cream with Alitretinoin Capsules in Adults With Severe Chronic Hand Eczema (CHE)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Timber Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LEO Pharma Finalizes Acquisition of Key Assets from Timber Pharmaceuticals","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Inc. Announces U.S. FDA approval of Adbry\u00ae (tralokinumab-ldrm) for the Treatment of Moderate-to-severe Atopic Dermatitis in Pediatric Patients Aged 12-17 Years","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals by Leo Pharma
LP0133 (delgocitinib) cream is an investigational, first-in-class, topical pan-Janus kinase (JAK) inhibitor for CHE. It is under phase 3 clinical development for the treatment of Moderate to Severe Chronic Hand Eczema.
Through the acquisition, LEO expand its pipeline by including TMB-001, an investigational topical reformulation of the active pharmaceutical ingredient, isotretinoin that today only exists in an oral formulation in the U.S.
Adbry (tralokinumab-ldrm) is the first treatment for pediatric patients with moderate-to-severe atopic dermatitis specifically targeting the interleukin (IL)-13 cytokine, one of the key drivers of atopic dermatitis signs and symptoms.
LP0133 (delgocitinib) is a first-in-class investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.
LEO 138559 (temtokibart) is an investigational monoclonal antibody that targets the IL-22RA1 receptor subunit, currently in Phase 2 development for the potential treatment of moderate-to-severe atopic dermatitis.
Lead Product(s):
Temtokibart
Therapeutic Area:DermatologyProduct Name: LEO 138559
Highest Development Status:Phase IIProduct Type: Large molecule
Through the acquisition, LEO gains rights to establish TMB-001, topical isotretinoin in Timber's patented IPEG™ delivery system, as the standard of care in the treatment of congenital ichthyosis, a devastating, rare disease.
LEO Pharma Receives Positive CHMP Opinion for New Adtralza (tralokinumab) Injection Device
Details:
Adtralza (tralokinumab), is a pre-filled pen Injection Device with high-affinity fully human monoclonal antibody developed to bind to and inhibit the interleukin (IL)-13 cytokine, which plays a role in the immune and inflammatory processes underlying atopic dermatitis and symptoms.
LEO 138559 is an investigational monoclonal antibody which blocks the IL-22RA1 receptor subunit thereby inhibiting the effect of the interleukin-22 (IL-22) cytokine, it is currently being developed for the treatment of moderate-to-severe atopic dermatitis.
Lead Product(s):
LEO 138559
Therapeutic Area:DermatologyProduct Name: LEO 138559
Highest Development Status:Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
LP0133 (delgocitinib) is a first-in-class investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.
Adtralza (tralokinumab), is the first and only approved human, monoclonal antibody developed to specifically target and neutralize the IL-13 cytokine, which plays a key role in immune and inflammatory process which are the underlying causes of atopic dermatitis.